Share on LinkedInShare on LinkedIn

ARTICLE · 04 MAY 2016

BIND Therapeutics, Inc. Files For Chapter 11 Protection

On May 1, 2016, BIND Therapeutics, Inc., and affiliated companies ("Debtors" or "BIND") voluntarily filed for bankruptcy protection under Chapter 11 of the Bankruptcy Code.

United StatesInsolvency/Bankruptcy/Re-Structuring

On May 1, 2016, BIND Therapeutics, Inc., and affiliated companies ("Debtors" or "BIND") voluntarily filed for bankruptcy protection under Chapter 11 of the Bankruptcy Code.

The filing comes days after the Cambridge, Mass., company received a notice of default from lender Hercules Technology III LP, which demanded immediate payment of the $14.5 million the lender says it is owed under the loan.  The Company is backed by Koch Industry Inc.'s David Koch.

According to the First Day Declaration of Andrew Hirsch, President and Chief Executive Officer of the Debtors,BIND is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer.  Bind Therapeutics' website says it is developing drug treatments that use nanoparticles to treat cancer.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from